Recursion Pharmaceuticals, Inc. RXRX Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Finance Lease, Right-of-Use Asset, after Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAsset.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s finance lease, right-of-use asset, after accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s finance lease, right-of-use asset, after accumulated amortization?
- Recursion Pharmaceuticals, Inc. (RXRX) reported finance lease, right-of-use asset, after accumulated amortization of $18.69M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s finance lease, right-of-use asset, after accumulated amortization changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s finance lease, right-of-use asset, after accumulated amortization decreased by 24.5% year-over-year, from $24.76M to $18.69M.